Skip to main content

Population Pharmacokinetics of Dexmedetomidine in Infants.

Publication ,  Journal Article
Greenberg, RG; Wu, H; Laughon, M; Capparelli, E; Rowe, S; Zimmerman, KO; Smith, PB; Cohen-Wolkowiez, M
Published in: J Clin Pharmacol
September 2017

Despite limited pharmacokinetic (PK) data, dexmedetomidine is increasingly being used off-label for sedation in infants. We aimed to characterize the developmental PK changes of dexmedetomidine during infancy. In this open-label, single-center PK study of dexmedetomidine in infants receiving dexmedetomidine per clinical care, ≤10 blood samples per infant were collected. A set of structural PK models and residual error models were explored using nonlinear mixed-effects modeling in NONMEM. Covariates including postmenstrual age (PMA), serum creatinine, and recent history of cardiac surgery requiring cardiopulmonary bypass were investigated for their influence on PK parameters. Univariable generalized estimating equation models were used to evaluate the association of hypotension with dexmedetomidine concentrations. A total of 89 PK samples were collected from 20 infants with a median PMA of 44 weeks (range, 33-61). The median maximum dexmedetomidine infusion dose during the study period was 1.8 μg/(kg·h) (0.5-2.5), and 16/20 infants had a maximum dose >1 μg/(kg·h). A 1-compartment model best described the data. Younger PMA was a significant predictor of lower clearance. Infants with a history of cardiac surgery had ∼40% lower clearance compared to those without a history of cardiac surgery. For infants with PMA of 33 to 61 weeks and body weight of 2 to 6 kg, the estimated clearance and volume of distribution were 0.87 to 2.65 L/(kg·h) and 1.5 L/kg, respectively. No significant associations were found between dexmedetomidine concentrations and hypotension. Infants with younger PMA and recent cardiac surgery may require relatively lower doses of dexmedetomidine to achieve exposure similar to older patients and those without cardiac surgery.

Duke Scholars

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

September 2017

Volume

57

Issue

9

Start / End Page

1174 / 1182

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • Models, Biological
  • Male
  • Infant, Newborn
  • Infant
  • Hypnotics and Sedatives
  • Humans
  • Female
  • Dexmedetomidine
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenberg, R. G., Wu, H., Laughon, M., Capparelli, E., Rowe, S., Zimmerman, K. O., … Cohen-Wolkowiez, M. (2017). Population Pharmacokinetics of Dexmedetomidine in Infants. J Clin Pharmacol, 57(9), 1174–1182. https://doi.org/10.1002/jcph.904
Greenberg, Rachel G., Huali Wu, Matthew Laughon, Edmund Capparelli, Stevie Rowe, Kanecia O. Zimmerman, P Brian Smith, and Michael Cohen-Wolkowiez. “Population Pharmacokinetics of Dexmedetomidine in Infants.J Clin Pharmacol 57, no. 9 (September 2017): 1174–82. https://doi.org/10.1002/jcph.904.
Greenberg RG, Wu H, Laughon M, Capparelli E, Rowe S, Zimmerman KO, et al. Population Pharmacokinetics of Dexmedetomidine in Infants. J Clin Pharmacol. 2017 Sep;57(9):1174–82.
Greenberg, Rachel G., et al. “Population Pharmacokinetics of Dexmedetomidine in Infants.J Clin Pharmacol, vol. 57, no. 9, Sept. 2017, pp. 1174–82. Pubmed, doi:10.1002/jcph.904.
Greenberg RG, Wu H, Laughon M, Capparelli E, Rowe S, Zimmerman KO, Smith PB, Cohen-Wolkowiez M. Population Pharmacokinetics of Dexmedetomidine in Infants. J Clin Pharmacol. 2017 Sep;57(9):1174–1182.

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

September 2017

Volume

57

Issue

9

Start / End Page

1174 / 1182

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • Models, Biological
  • Male
  • Infant, Newborn
  • Infant
  • Hypnotics and Sedatives
  • Humans
  • Female
  • Dexmedetomidine
  • 3214 Pharmacology and pharmaceutical sciences